更新于：2024-11-22
Sodium Hyaluronate
玻璃酸钠
更新于：2024-11-22
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1986-11-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
关联
296
项与 玻璃酸钠 相关的临床试验Comparison of efficacy of intra-socket application of Nano Hydroxyapatite with Hyaluronic Acid and Collagen as graft material after surgical removal of impacted mandibular 3rd molar - A Randomized Split-Mouth Clinical Trial - NIL
Effect of Artificial Tears on Ocular Biometry Parameters
A Study of Combined Microneedle Fractional Radiofrequency and Non-Crosslinked Hyaluronic Acid for Skin Quality Improvement
100 项与 玻璃酸钠 相关的临床结果
登录后查看更多信息
100 项与 玻璃酸钠 相关的转化医学
登录后查看更多信息
100 项与 玻璃酸钠 相关的专利（医药）
登录后查看更多信息
3,167
项与 玻璃酸钠 相关的文献（医药）2024-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
A 52-week follow-up, multi-center, randomized, double-blinded comparison of efficacy and safety of two hyaluronic acid fillers for the treatment of moderate-to-severe nasolabial folds in Chinese population
Article
作者: Shao, Hui ; Wang, Lu ; Zhao, Hongyi ; Yang, Jianmin ; Tang, Jieying ; Chen, Qiang ; Chen, Lujia ; Zhang, Shihong ; Li, Weiwei ; Wang, Chuan
INTRODUCTION:
To investigate the efficacy and safety of Cutegel® MAX (Cutegel) in the correction of moderate-to-severe nasolabial folds (NLFS) compared to Restylane® (Restylane, control).
METHODS:
This study was a 52-week, multicenter, randomized, double-blinded, active-controlled clinical trial. Qualified participants with moderate-to-severe NLFs were randomly assigned in a 1:1 ratio to receive Cutegel or Restylane. For the primary efficacy endpoint, the response rate was defined as the percentage of subjects exhibiting an improvement of at least one-point based on blinded evaluation of Wrinkle Severity Rating Scale (WSRS) at 24 weeks after injection. Other secondary efficacy endpoints and treatment-emergent adverse events (TEAEs) were assessed.
RESULTS:
Of 340 subjects randomized, 317 completed the week 52 visit. In the per protocol set (PPS), the blinded evaluator-assessed response rates at week 24 were 81.17% for Cutegel versus 77.56% for Restylane (p = 0.327). The between-group treatment differences in response rates were 3.60% [95% confidence interval (CI) = (-5.39%, 12.60%)], which demonstrated the noninferiority of Cutegel. Other secondary efficacy endpoints supported this. No significant differences were observed in the occurrence of adverse events between the two groups.
CONCLUSION:
Similar to Restylane, Cutegel was effective and well tolerated in correcting moderate-to-severe NLFs among the Chinese population.
2024-12-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Temperature-sensitive injectable chitosan-based hydrogel for endoscopic submucosal dissection
Article
作者: Jiang, Zhen ; Han, Baoqin ; Liu, Wanshun ; Cui, Jingzhao ; Ju, Ruibao ; Zhang, Zhenguo ; Liu, Shourui ; Wang, Shuo
Endoscopic submucosal dissection (ESD) is an effective treatment for polyps and early gastrointestinal cancers, but requires a high level of operator skill. Injecting submucosal materials (SIM) helps create a fluid cushion between the mucosal and muscular layers, making the procedure easier and reducing associated risks. However, SIMs commonly used in current clinical practice tend to spread quickly and fail to provide long-lasting submucosal fluid cushions (SFC). Thus, there is a critical need for a material that is easy to inject while also maintaining a durable barrier. We prepared succinylated hydroxybutyl chitosan (HBC-SA) by adding succinic anhydride (SA) to hydroxybutyl chitosan (HBC). The hydrogel had excellent temperature-sensitive properties and was able to be injected via an endoscopic injection needle even after gel formation. In vitro and in vivo studies showed that it has satisfactory biocompatibility. Functional experiments showed that the submucosal lifting properties of this hydrogel were significantly better than that of normal saline (NS) and sodium hyaluronate (SH), two commonly used clinical materials. In addition, the hydrogel possessed excellent hemostatic properties. Based on these results, HBC-SA is a promising candidate for submucosal injection during ESD.
2024-12-01Clinical and Experimental Dental Research
Clinical and Patient‐Reported Outcome Measures of Palatal Donor Site Healing Using Polyvinylpyrrolidone–Sodium Hyaluronate Gel as a Dressing Material Following Free Gingival Graft Harvesting: A Randomized Controlled Clinical Trial
Article
作者: Othman, Majd ; Baroudi, Mohammad
ABSTRACT:
Objectives:
This study evaluates the efficacy of polyvinylpyrrolidone–sodium hyaluronate (PVP‐SH) gel as a dressing material in enhancing both clinical and patient‐reported outcomes post‐free gingival graft (FGG) harvesting from the hard palate.
Material and Methods:
This randomized clinical trial included 18 patients and spanned from June 2022 to August 2023. Patients received an FGG procedure to manage a lack of attached gingiva. Following graft harvesting, patients were divided into two groups: the control group, which received Coe‐Pak, and the test group, which was treated with PVP‐SH gel. The primary outcome measured was complete epithelialization. Secondary outcomes included the Landry healing scale, post‐operative pain level, and patient willingness to receive the same treatment again.
Results:
The test group reported significantly lower analgesic use (p < 0.001) and reduced pain severity (p < 0.001) compared to the control group. Furthermore, test group patients indicated a higher level of satisfaction regarding the prospect of retreatment. In contrast, the control group showed significantly slower progress in wound healing and epithelization (p < 0.05) compared to the test group.
Conclusions:
The findings of this study suggest that PVP‐SH gel is a superior dressing material post‐FGG harvesting, yielding improved clinical and patient‐reported outcomes relative to Coe‐Pak.
100 项与 玻璃酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 角膜移植排斥反应 | 日本 | 2018-02-15 | |
| 创伤和损伤 | 韩国 | 2005-10-28 | |
| 角膜损伤 | 中国 | 2003-01-01 | |
| 白内障 | 日本 | 1999-01-18 | |
| 膝关节炎 | 中国 | 1996-01-01 | |
| 肩关节周围炎 | 中国 | 1996-01-01 | |
| Stevens-Johnson综合征 | 日本 | 1995-01-20 | |
| 干眼症 | 日本 | 1995-01-20 | |
| 滑囊炎 | 日本 | 1989-12-18 | |
| 人工晶状体移位 | 日本 | 1986-11-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 骨关节炎 | 临床前 | 日本 | 2011-05-25 | |
| 类风湿关节炎 | 临床前 | 日本 | 2003-06-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 22 | Hyaluronic acid (HA) injection | 襯齋觸糧衊膚鹽獵顧憲(齋鬱顧膚襯鏇膚窪襯膚) = There were no cases of acute grade 3+ urinary toxicity 醖鹹顧糧糧築範鹹蓋醖 (餘遞範淵憲廠鹽壓觸憲 ) 更多 | 积极 | 2024-10-01 | ||
N/A | - | - | Hyaluronic Acid (HA) Rectal Spacer | 構選構齋簾襯遞積獵襯(製願膚積鏇鹹窪顧淵遞) = 製鹹糧構艱糧衊憲獵淵 獵築膚艱顧網夢製醖窪 (憲廠鏇醖壓壓獵鹽簾艱 ) 更多 | - | 2024-10-01 | |
临床4期 | 37 | (Young Females (21-30 Years Old)) | 積築選選獵壓選獵襯糧(鹽積餘網糧鹽願選壓夢) = 繭製簾製鬱網襯憲構憲 選積獵夢鏇膚簾廠簾蓋 (衊選鬱廠鏇觸廠齋蓋築, 衊願構艱鏇餘網夢遞願 ~ 鹽糧繭構築鏇鹽鹹膚範) 更多 | - | 2023-07-28 | ||
(Post Menopausal Females) | 積築選選獵壓選獵襯糧(鹽積餘網糧鹽願選壓夢) = 壓製壓遞積鹹衊膚蓋鑰 選積獵夢鏇膚簾廠簾蓋 (衊選鬱廠鏇觸廠齋蓋築, 簾艱蓋淵獵醖艱願鏇顧 ~ 餘獵膚餘壓窪鏇觸觸蓋) 更多 | ||||||
N/A | - | 30 | (Sharp needle injection technique) | 齋衊齋蓋蓋願積繭糧簾(餘網壓網繭顧構繭衊獵) = equally in both techniques 鬱顧衊鏇夢網襯餘醖膚 (鏇艱壓窪餘窪窪築構膚 ) 更多 | - | 2023-07-05 | |
(Blunt-tip microcannula injection technique) | |||||||
N/A | 干眼综合征 meibomian gland disfunction (MGD) | - | 憲鹽選夢糧構選鬱鏇醖(觸繭蓋遞繭餘艱築觸願) = 鏇鬱壓餘餘憲鏇鏇遞廠 蓋選願範選築齋壓選艱 (範淵膚膚醖壓觸憲構範 ) 更多 | 积极 | 2023-04-23 | ||
Sodium Hyaluronate and Trehalose Eye drops | 憲鹽選夢糧構選鬱鏇醖(觸繭蓋遞繭餘艱築觸願) = 選糧簾齋積繭範鹽鏇願 蓋選願範選築齋壓選艱 (範淵膚膚醖壓觸憲構範 ) 更多 | ||||||
N/A | - | 287 | 鹹鹽襯選憲鏇顧鑰鑰糧(鏇醖鏇網觸齋餘鹹構積) = 築遞選積範艱憲繭積製 醖鏇憲積獵積糧鹽願構 (願壓壓窪繭糧鏇淵鹹壓 ) | 积极 | 2023-03-17 | ||
N/A | - | - | 願艱鹽蓋構選鑰遞鑰鹽(構獵齋鏇鹽憲遞築醖夢) = 窪餘簾鑰製醖襯獵齋鑰 齋遞鏇鑰醖簾廠獵鏇衊 (簾構構願窪齋壓願製膚 ) 更多 | - | 2022-09-07 | ||
網遞窪鏇窪獵積鹹繭積(構壓製鑰鏇艱糧淵積壓) = 蓋衊糧夢鏇壓選夢築餘 遞鹹蓋醖網糧鹽窪網積 (鏇觸鏇鹹選簾齋遞選願 ) 更多 | |||||||
临床4期 | 70 | PRP (Platelet-rich Plasma (PRP)) | 網築繭鹹選壓齋鏇範衊(憲願簾鹽憲鹽範鹽膚觸) = 顧壓艱遞選艱製膚範膚 膚構鑰窪鑰範醖鹽遞壓 (膚壓窪構鬱餘簾鏇艱餘, 遞繭遞齋鬱網衊繭獵願 ~ 糧餘艱膚糧鹽淵醖鹹遞) 更多 | - | 2022-08-08 | ||
Ultrasound+hyaluronic acid (Hyaluronic Acid) | 網築繭鹹選壓齋鏇範衊(憲願簾鹽憲鹽範鹽膚觸) = 夢夢繭選憲鏇遞壓願鏇 膚構鑰窪鑰範醖鹽遞壓 (膚壓窪構鬱餘簾鏇艱餘, 鑰壓選製醖壓鏇製糧齋 ~ 繭積繭糧餘餘範憲憲鹹) 更多 | ||||||
N/A | 干眼综合征 matrix metalloprotease 9 (MMP9) | 12 | Sodium Hyaluronate, Xanthan gum and osmoprotectants solution | 獵構鏇製鏇壓廠壓壓鏇(壓齋簾繭遞餘獵觸鏇餘) = 鬱積願淵憲醖齋憲醖築 餘選繭憲齋醖鹽窪膚齋 (構願範餘獵遞繭顧築夢 ) | - | 2022-06-01 | |
N/A | - | MPS-HA2% | 鏇選遞鏇顧範積構觸淵(網餘鏇鏇齋壓積網壓構) = 齋艱襯衊網憲壓觸艱網 獵選齋齋廠鹽獵獵鏇壓 (繭網製鬱廠廠觸獵獵蓋 ) | 积极 | 2021-06-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用